BRCA2 and neoplasm: When homologous recombination repair defects present in tumor cells (such as BRCA1 and BRCA2 mutations) that make DSB damage unrepairable, PARP inhibitors and homologous recombination repair defects react in the lethal synthesis of tumor cells [6].